Alnylam Pharmaceuticals (ALNY) Tax Provisions (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Tax Provisions came in at $13.3 million in Q2 2026, down 56.95% YoY from $30.9 million in Q2 2025, and down 15.0% on a QoQ basis from $15.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Tax Provisions (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 14 years of Tax Provisions data on file, last reported at $13.3 million in Q2 2026.
- Quarterly Tax Provisions fell 56.95% year-over-year to $13.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$8.4 million (up 86.07% YoY) and the FY2025 annual result came in at $9.4 million, up 109.48% from the prior year.
- Tax Provisions slipped to $13.3 million in Q2 2026, from $15.7 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $30.9 million in Q2 2025 to a low of -$110.2 million in Q4 2024.
- A 5-year average of -$2.8 million and a median of $2.1 million in 2023 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions soared 13091.3% — and 2024, when it tumbled 60315.85%.
- Tracing ALNY's Tax Provisions over 5 years: stood at $472000.0 in 2022, then slumped by 61.23% to $183000.0 in 2023, then plunged by 60315.85% to -$110.2 million in 2024, then jumped by 77.06% to -$25.3 million in 2025, then soared by 152.65% to $13.3 million in 2026.
- The last three Tax Provisions figures came in at $13.3 million (Q2 2026), $15.7 million (Q1 2026), and -$25.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.31 Mn |
| Mar 31, 2026 | 15.66 Mn |
| Dec 31, 2025 | -25.29 Mn |
| Sep 30, 2025 | -12.12 Mn |
| Jun 30, 2025 | 30.92 Mn |
| Mar 31, 2025 | 15.88 Mn |
| Dec 31, 2024 | -110.20 Mn |
| Sep 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 183,000.00 |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 472,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | 2.73 Mn |
| Mar 31, 2022 | 985,000.00 |
| Dec 31, 2021 | -1.84 Mn |
| Sep 30, 2021 | 278,000.00 |